Literature DB >> 15627900

Interfering with cancer: a brief outline of advances in RNA interference in oncology.

P D Rye1, T Stigbrand.   

Abstract

RNA interference (RNAi) is a potent and ubiquitous gene-silencing mechanism that is generating considerable excitement in the fields of molecular biology and gene therapy. It is now in widespread use for loss-of-function analysis in many diseases including cancer. Nevertheless, RNAi is still in its infancy, with new discoveries appearing on a monthly basis. This article presents a brief outline of the history and recent advances in RNAi with a specific focus on its potential in oncology. Copyright 2004 S. Karger AG, Basel.

Entities:  

Mesh：

Year:  2004        PMID： 15627900     DOI： 10.1159/000081403

Source DB:  PubMed          Journal:  Tumour Biol        ISSN： 1010-4283


  6 in total

1.  WT1 silencing by RNAi synergizes with chemotherapeutic agents and induces chemosensitization to doxorubicin and cisplatin in B16F10 murine melanoma cells.

Authors:  Pablo Zapata-Benavides; Edgar Manilla-Muñoz; Diana E Zamora-Avila; Santiago Saavedra-Alonso; Moisés A Franco-Molina; Laura M Trejo-Avila; Guillermo Davalos-Aranda; Cristina Rodríguez-Padilla
Journal:  Oncol Lett       Date:  2012-01-19       Impact factor: 2.967

2.  p53siRNA therapy reduces cell proliferation, migration and induces apoptosis in triple negative breast cancer cells.

Authors:  Cornelia Braicu; Valentina Pileczki; Alexandru Irimie; Ioana Berindan-Neagoe
Journal:  Mol Cell Biochem       Date:  2013-06-04       Impact factor: 3.396

3.  Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells.

Authors:  Theodore S Nowicki; Hong Zhao; Zbigniew Darzynkiewicz; Augustine Moscatello; Edward Shin; Stimson Schantz; Raj K Tiwari; Jan Geliebter
Journal:  Cell Cycle       Date:  2011-01-01       Impact factor: 4.534

4.  The role of Med19 in the proliferation and tumorigenesis of human hepatocellular carcinoma cells.

Authors:  Shao-wu Zou; Kai-xing Ai; Zhi-gang Wang; Zhou Yuan; Jun Yan; Qi Zheng
Journal:  Acta Pharmacol Sin       Date:  2011-03       Impact factor: 6.150

5.  RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.

Authors:  Sai MuraliKrishna Pulukuri; Christopher S Gondi; Sajani S Lakka; Aman Jutla; Norman Estes; Meena Gujrati; Jasti S Rao
Journal:  J Biol Chem       Date:  2005-08-26       Impact factor: 5.157

6.  The neonatal splice variant of Nav1.5 potentiates in vitro invasive behaviour of MDA-MB-231 human breast cancer cells.

Authors:  William J Brackenbury; Athina-Myrto Chioni; James K J Diss; Mustafa B A Djamgoz
Journal:  Breast Cancer Res Treat       Date:  2006-07-13       Impact factor: 4.872
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.